Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Karthiek R Narala , Thomas A LaLonde , Sohail Hassan , et al Added: 3 years ago
Chronic kidney disease (CKD) affects approximately 26 million people in the US.1 CKD is considered a coronary risk equivalent and also a risk factor for progression of cardiovascular disease (CVD).2 Cardiovascular death rates are 10–30 times higher in dialysis patients than in the general population.3 This increase in CKD patients is multifactorial and is now mainly considered via two pathways:… View more

Anticoagulation
ACC 2020: Inclisiran Potently and Durably Reduces Ldl-c
Added: 3 years ago
Dr R Scott Wright (Mayo Clinic, Rochester, MN, US) summarises a pooled analyses of phase 3 studies showing how Inclisiran potently and durably reduces Ldl-c. Questions: 1. What prompted the study? 2. How does Inclisiran work? 3. What is the study design? 4. Who were the patients? 5. What were the efficacy results? 6. What were the safety findings? 7. What are the implications of this… View more

Prevention & Chronic Conditions
Author(s): Raif Tawakol Added: 3 years ago
Many patients on statin therapy understandably develop a false sense of security. They enjoy a lowered level of low-desity lipoprotein (LDL) and a risk reduction of some 35%. However, two out of three patients develop a myocardial infarction (MI) while on a statin therapy. Statins often do not increase HDL levels to any substantial degree (except for Rosuvastatin, which increases high-density… View more

Prevention & Chronic Conditions
Author(s): Sergio Fazio Added: 3 years ago
The wide utilization of anti-cholesterol agents, such as the statins, has created confusion among patients and clinicians about what to do when the lipid problem is one of triglycerides and high-density lipoprotein (HDL), rather than one of low density lipoprotein (LDL). Although most patients with diabetes have a dyslipidemia characterized by high triglycerides and low HDL (atherogenic… View more

Prevention & Chronic Conditions
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study
Author(s): Annapoorna Kini Added: 1 year ago
ACC.23/WCC — Principle investigator of YELLOW III, Dr Annapoorna Subhash Kini(Mount Sinai Hospital, US) joins us to talk about the study that assessed the effect of evolocumab (Repatha) on coronary plaque morphology using intravascular imaging and gene expression analysis of peripheral blood mononuclear cells (PBMC) in 140 patients with stable CAD on maximally tolerated statin therapy … View more

Imaging & Diagnostics

Prevention & Chronic Conditions
Author(s): Jakub Podolec , Lukasz Niewiara Added: 3 years ago
Atherosclerosis is the primary cause of coronary artery disease morbidity and mortality worldwide.1 Low-density lipoprotein cholesterol (LDL-C)- lowering therapies have already become one of the most important in the prevention of atherosclerosis complications.2 Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) and thus significantly… View more

Prevention & Chronic Conditions
Author(s): Kilmer S McCully Added: 3 years ago
Discovery of the Homocysteine Theory of Arteriosclerosis The American biochemist Vincent DuVigneaud discovered a new amino acid in 1932 by treating methionine with sulfuric acid. The structure of this amino acid is similar to cysteine, except for one extra carbon atom, hence the name homocysteine. Subsequent investigation established the role of homocysteine as an intermediate in sulfur amino… View more

Prevention & Chronic Conditions
Author(s): Kilmer S McCully Added: 3 years ago
Discovery of the Homocysteine Theory of Arteriosclerosis The American biochemist Vincent DuVigneaud discovered a new amino acid in 1932 by treating methionine with sulfuric acid. The structure of this amino acid is similar to cysteine, except for one extra carbon atom, hence the name homocysteine. Subsequent investigation established the role of homocysteine as an intermediate in sulfur amino… View more

Prevention & Chronic Conditions
ACC 22: Results from the TRANSLATE-TIMI 70 Trial
Author(s): Brian Bergmark Added: 2 years ago
In this short interview from our coverage of the ACC.22 late-breaking trials, Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) discusses the data from the TRANSLATE-TIMI 70 study; a phase 2b, randomised trial of vupanorsen (an antisense oligonucleotide)(NCT04516291). The primary objective was to evaluate the effect of vupanorsen on non-high-density lipoprotein (non-HDL… View more

Prevention & Chronic Conditions
Author(s): Robert A Vogel Added: 3 years ago
There are about 65 million Americans (or 20–25% of the population) with hypertension.As a top line figure that is probably a little low as it uses the rather strict definition of high blood pressure as being 140 over 90.Hypertension is also very strongly age-related, and as we get older that frequency goes up a lot. Essentially, 95% of Americans will be hypertensive in their lifetime. It is a… View more

Prevention & Chronic Conditions